Tarsus Pharmaceuticals Inc (NASDAQ: TARS) on Tuesday, plunged -4.81% from the previous trading day, before settling in for the closing price of $47.84. Within the past 52 weeks, TARS’s price has moved between $20.08 and $57.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -21.79% annually for the last half of the decade. The company achieved an average annual earnings per share of 31.35%. With a float of $32.95 million, this company’s outstanding shares have now reached $38.20 million.
In an organization with 244 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 92.97%, operating margin of -108.47%, and the pretax margin is -103.64%.
Tarsus Pharmaceuticals Inc (TARS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tarsus Pharmaceuticals Inc is 13.81%, while institutional ownership is 102.33%. The most recent insider transaction that took place on Aug 12 ’24, was worth 912,961. In this transaction Director of this company sold 35,000 shares at a rate of $26.08, taking the stock ownership to the 0 shares. Before that another transaction happened on Aug 12 ’24, when Company’s Director proposed sale 35,000 for $26.85, making the entire transaction worth $939,750.
Tarsus Pharmaceuticals Inc (TARS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 31.35% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
Tarsus Pharmaceuticals Inc (TARS) is currently performing well based on its current performance indicators. A quick ratio of 5.38 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.81, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -1.54 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.56 million. That was inferior than the volume of 0.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 5.26%. Additionally, its Average True Range was 2.52.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 54.18%, which indicates a significant increase from 0.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.16% in the past 14 days, which was lower than the 46.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.68, while its 200-day Moving Average is $38.58. However, in the short run, Tarsus Pharmaceuticals Inc’s stock first resistance to watch stands at $47.33. Second resistance stands at $49.12. The third major resistance level sits at $50.04. If the price goes on to break the first support level at $44.62, it is likely to go to the next support level at $43.70. Assuming the price breaks the second support level, the third support level stands at $41.91.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
Market capitalization of the company is 1.74 billion based on 38,227K outstanding shares. Right now, sales total 17,450 K and income totals -135,890 K. The company made 48,120 K in profit during its latest quarter, and -23,420 K in sales during its previous quarter.
